France urothelial carcinoma market is estimated to grow considerably, at a CAGR of around 9.6% during the forecast period. France is one of the leading economies and technologically advanced countries in Europe. France has a quality healthcare system and favorable government policies which is augmenting the growth of the market in France. The number of new cases associated with bladder cancer is less than that of other economies of the region. Bladder cancer cases accounted for nearly 3.6% of the total cases registered in 2018. In 2018, the total number of new cases of cancer was recorded to be 455,618 out of which 16,282 cases were registered for bladder cancer. Furthermore, bladder cancer cases were registered more for men as compared to women. Furthermore, the total number of deaths caused due to bladder cancer in France was about 7,198. These figures show significant potential for the growth of the market in the near future. Moreover, the healthcare expenditure in France is high which is around 10% of the total GDP of France. Furthermore, according to French National Cancer Institute, between 2007-2016 nearly $1.05 billion were invested in research and development of cancer treatment. As this increase, it is expected to promote the growth of the market over the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-urothelial-carcinoma-market
France urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. There are several companies, such as Nucleix, Ltd. that have introduced biomarkers for the diagnosis of urothelial carcinoma. The high accuracy and speedy diagnosis claim to be a beneficiary factor of the biomarkers that are involved in its increasing adoption for the diagnosis of urothelial carcinoma.
The companies which are contributing to the growth of France urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Sanofi SA, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
France Urothelial Carcinoma Market- Segmentation
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of France Urothelial Carcinoma Market is available at: https://www.omrglobal.com/industry-reports/france-urothelial-carcinoma-market
